26 research outputs found
Efficacy of Erlotinib in patients (PTS) with advanced non-small-cell lung cancer (NSCLC) relative to clinical charesteristics : subset analyses from the trust study
peer reviewe
Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC).
Niet-kleincellige longkanker : classificatie van de "International Association for Study of Lung Cancer" (IASLC) 2007
Phase II trial exploring gemcitabine and cisplatin as treatment of patients with non-small cell lung cancer (NSCLC) and inoperable brain metastases
Efficacy and Morbidity of a Novel Induction Treatment in Locally Advanced Non Small Cell Lung Cancer (NSCLC)
Lung cancer. Epidemiology and etiologic factors
peer reviewedLung cancer is the most frequent cause of death by cancer worldwide. Despite improvements in the treatment the vital prognosis remains poor with an estimated 5-year survival rate of 15 % all stages together. Even if some environmental exposure may favour apparition of the disease, tobacco smoking is by far the greatest risk factor for developing lung cancer. Recent progresses have been made on the identification of cellular mechanisms and genetic abnormalities that make the patients more prone to develop lung cancer
Therapeutic Update in Respiratory Medicine
peer reviewedWe review what we think to be the major advances in the field of respiratory medicine over the last ten years. We concentrate here on four major diseases i.e. asthma, chronic obstructive pulmonary disease (COPD), lung cancer and chronic respiratory insufficiency due to restrictive disorders. Therapeutic advances are based either on new drugs or on new disease management concepts and, in some cases, on new medical devices. These advances have allowed a reduction in mortality and morbidity in aforementioned diseases
Update in Treatment of Non Small Cell Lung Cancer
Surgery, chemotherapy, radiotherapy and "biological" treatment are differently used in the treatment of non small cell lung cancer. Surgery is the cornerstone of the stages I-II treatment; chemotherapy is dominant in the treatment of metastatic stage, but is more and more used in earlier stages. A large discussion is still open for advanced non metastatic stages, even if the association of the 3 major modalities is extensively studied. We discuss our position in this setting